Filing Flows › Pacira BioSciences (PCRX) › R&D spending
Pacira BioSciences (PCRX) R&D spending by quarter
Pacira BioSciences' R&D spending was $26.7M in Q3 2026 (third quarter 2026), -12% from Q2 2026. Over the last 7 quarters it ranged from $25.3M (Q1 2025) to $37.5M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $26.7M | -12% | +3% |
| Q2 2026 | $30.2M | +8% | +7% |
| Q1 2026 | $28.1M | -25% | +11% |
| Q4 2025 | $37.5M | +44% | — |
| Q3 2025 | $26.0M | -8% | — |
| Q2 2025 | $28.2M | +11% | — |
| Q1 2025 | $25.3M | — | — |
Q3 2026 at a glance
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pacira BioSciences' R&D spending?
Pacira BioSciences' R&D spending was $26.7M in Q3 2026 (third quarter 2026), -12% from Q2 2026.
How has Pacira BioSciences' R&D spending changed?
Over the last 7 quarters it ranged from $25.3M (Q1 2025) to $37.5M (Q4 2025).